AlzeCure Pharma Investor Relations Material

AlzeCure Pharma AB is a Swedish pharmaceutical company focused on developing treatments for severe diseases related to the central nervous system, particularly Alzheimer's disease. The company operates primarily through two research platforms: NeuroRestore, aimed at restoring cognitive functions by stimulating essential brain signaling pathways, and Alzstatin, which targets reducing the production of amyloid beta, a key factor in Alzheimer's pathology. AlzeCure's drug pipeline includes ACD856, a candidate for treating Alzheimer's, depression, and traumatic brain injuries, currently in phase I clinical trials, as well as several other preclinical candidates for pain and neurodegenerative conditions. AlzeCure is headquartered in Stockholn, Sweden, and its shares are listed on the Nasdaq Stockholm.